Westside Investment Management Inc. Has $2.74 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Westside Investment Management Inc. lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,447 shares of the biopharmaceutical company's stock after selling 2,898 shares during the quarter. Westside Investment Management Inc.'s holdings in Gilead Sciences were worth $2,736,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Goodman Advisory Group LLC acquired a new position in Gilead Sciences in the 1st quarter valued at approximately $29,000. Annis Gardner Whiting Capital Advisors LLC grew its holdings in shares of Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 216 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in shares of Gilead Sciences during the 4th quarter valued at $35,000. Synergy Investment Management LLC acquired a new position in shares of Gilead Sciences in the fourth quarter worth $40,000. Finally, Lee Danner & Bass Inc. purchased a new stake in shares of Gilead Sciences during the fourth quarter worth $41,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction on Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer now directly owns 620,268 shares in the company, valued at approximately $68,489,992.56. This represents a 1.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $330,510.00. Following the completion of the transaction, the insider now directly owns 120,168 shares of the company's stock, valued at approximately $13,238,908.56. This trade represents a 2.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,500 shares of company stock valued at $5,236,245. Insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

GILD opened at $110.67 on Monday. Gilead Sciences, Inc. has a 12-month low of $66.01 and a 12-month high of $119.96. The firm has a market capitalization of $137.67 billion, a P/E ratio of 23.30, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29. The stock's 50 day moving average price is $106.39 and its two-hundred day moving average price is $103.42. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. Gilead Sciences's quarterly revenue was down .3% on a year-over-year basis. During the same quarter last year, the company posted ($1.32) earnings per share. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.86%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on GILD. Morgan Stanley boosted their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Bank of America lifted their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Oppenheimer dropped their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.